Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organ-allograft recipients

被引:46
作者
Barete, S
Calvez, V
Mouquet, C
Barrou, B
Kreis, H
Dantal, J
Dorent, R
Durand, F
Dimitrov, Y
Dupin, N
Marcelin, AG
Piette, JC
Bitker, MO
Francès, C
机构
[1] Pitie Salpetriere Hosp, Dept Internal Med, Paris, France
[2] Pitie Salpetriere Hosp, Dept Renal Transplantat, Paris, France
[3] Pitie Salpetriere Hosp, Dept Virol, Paris, France
[4] Pitie Salpetriere Hosp, Dept Heart Transplantat, Paris, France
[5] Necker Hosp, Dept Renal Transplantat, Paris, France
[6] Hotel Dieu Hosp, Dept Renal Transplantat, Nantes, France
[7] Beaujon Hosp, Dept Liver Transplantat, Clichy, France
[8] Civil Hosp, Renal Transplantat Unit, Strasbourg, France
关键词
D O I
10.1001/archderm.136.12.1452
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objectives: To describe the clinical features of Kaposi sarcoma (KS) in organ-allograft recipients and to determine the contribution of human herpesvirus 8 (HHV-8) investigations to the management of KS. Design, Setting, and Patients: We examined 20 organ-allograft recipients with KS at Pitie-Salpetriere Hospital, Paris, France, between November 1, 1991, and May 31, 1999. Methods: We detected HHV-8 antibodies using an indirect immunofluorescence assay and the HHV-8 DNA genome using nonnested polymerase chain reaction with KS-associated herpesvirus 330(233) primers in peripheral blood mononuclear cells collected at transplantation and KS diagnosis. We detected the HHV-8 genome in involved and uninvolved tissue specimens and in 10 patients' serum samples collected 1 month before the first manifestation of KS. We determined the HHV-8 double-strand DNA sequence and subtypes of open reading frame 26. Intervention: Management of KS consisted of progressively tapering immunosuppressive therapy regardless of KS dissemination. Associated infections were treated when possible. Chemotherapy was prescribed only when a functional disability persisted, and polychemotherapy was prescribed for life-threatening disease. Main Outcome Measures: Percentage of recipients with KS remission and stabilization, organ-graft survival, and death rates. Results: Remission of KS was obtained in 9 (45%) of the 20 patients independently of disease dissemination, with a mean follow-up of 35 months. The kidney graft survived in 12 (67%) of the 18 patients. Only 1 patient (5%) died of KS progression. All allograft recipients had anti-HHV-8 antibodies before transplantation. We detected HHV-8 DNA in all involved tissue samples but not in serum samples 1 month before KS onset. The most prevalent subtype was HHV-8 C (9 [53%] of 17 patients) and was not associated with extradermatological extension of KS compared with subtypes A and B'. Conclusions: Virological investigations of HHV-8 contribute poorly to KS management. Prospective studies are needed to determine the role of HHV-8 virological investigations and to identify associated cofactors so as to prevent KS in organ-allograft recipients.
引用
收藏
页码:1452 / 1458
页数:7
相关论文
共 29 条
  • [11] Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients
    Farge, D
    Lebbé, C
    Marjanovic, Z
    Tuppin, P
    Mouquet, C
    Peraldi, HN
    Lang, P
    Hiesse, C
    Antoine, C
    Legendre, C
    Bedrossian, J
    Gagnadoux, HF
    Loirat, C
    Pellet, C
    Sheldon, J
    Golmard, JL
    Agbalika, F
    Schulz, TF
    [J]. TRANSPLANTATION, 1999, 67 (09) : 1236 - 1242
  • [12] Farge D, 1993, Eur J Med, V2, P339
  • [13] Kaposi's sarcoma after renal transplantation
    Frances, C
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (11) : 2768 - 2773
  • [14] Outcome of kidney transplant recipients with previous human herpesvirus-8 infection
    Francès, C
    Mouquet, C
    Marcelin, AG
    Barete, S
    Agher, R
    Charron, D
    Benalla, H
    Dupin, N
    Piette, JC
    Bitker, MO
    Calvez, V
    [J]. TRANSPLANTATION, 2000, 69 (09) : 1776 - 1779
  • [15] KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma
    Gao, SJ
    Kingsley, L
    Li, M
    Zheng, W
    Parravicini, C
    Ziegler, J
    Newton, R
    Rinaldo, CR
    Saah, A
    Phair, J
    Detels, R
    Chang, Y
    Moore, PS
    [J]. NATURE MEDICINE, 1996, 2 (08) : 925 - 928
  • [16] Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells
    Grandadam, M
    Dupin, N
    Calvez, V
    Gorin, I
    Blum, L
    Kernbaum, S
    Sicard, D
    Buisson, Y
    Agut, H
    Escande, JP
    Huraux, JM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (05) : 1198 - 1201
  • [17] Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs - Implications for potential therapy
    Kedes, DH
    Ganem, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (09) : 2082 - 2086
  • [18] KROWN SE, 1998, J NATL CANC I MONOGR, V23, P59
  • [19] Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma
    Lebbé, C
    Blum, L
    Pellet, C
    Blanchard, G
    Vérola, O
    Morel, P
    Danne, O
    Calvo, F
    [J]. AIDS, 1998, 12 (07) : F45 - F49
  • [20] CLINICAL-FEATURES AND COURSE OF KAPOSIS-SARCOMA IN KIDNEY-TRANSPLANT PATIENTS - REPORT OF 13 CASES
    MONTAGNINO, G
    BENCINI, PL
    TARANTINO, A
    CAPUTO, R
    PONTICELLI, C
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 1994, 14 (02) : 121 - 126